ADC Therapeutics SA
Company Profile
Business description
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Contact
Route de la Corniche 3B
Biopole
Epalinges1066
CHET: +41 216530200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
263
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,287.90 | 84.00 | 1.02% |
| CAC 40 | 7,550.49 | 23.27 | -0.31% |
| DAX 40 | 22,396.10 | 124.43 | 0.56% |
| Dow JONES (US) | 40,227.59 | 114.09 | 0.28% |
| FTSE 100 | 8,438.04 | 20.70 | 0.25% |
| HKSE | 22,008.11 | 36.15 | 0.16% |
| NASDAQ | 17,366.13 | 16.81 | -0.10% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,025.45 | 73.44 | -0.61% |
| S&P 500 | 5,528.75 | 3.54 | 0.06% |
| S&P/ASX 200 | 8,070.60 | 73.50 | 0.92% |
| SSE Composite Index | 3,286.65 | 1.76 | -0.05% |